AIM To assess whether the effectiveness of a combination of transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) in the treatment of unresectable hepatocellular carcinoma (HCC) is superior to TACE alone a randomized controlled trial was performed. METHODS The effect of combination therapy on long-term survival rates and duration of hospitalization was evaluated in 5...

UNLABELLED Transarterial chemoembolization (TACE) improves survival in patients with hepatocellular carcinoma (HCC) in whom curative therapies are not suitable. The aim of this study was to assess survival differences in patients with hepatic cirrhosis and unresectable HCC treated by (131)I-lipiodol versus TACE or transarterial embolization (TAE). METHODS A retrospective study was performed o...

Background: Outcome after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) is highly variable. Aims: To identify factors affecting outcome after TACE forHCC. Methods: We conducted a retrospective analysis of HCC patients treated with TACE from January 2001 to December 2010 at the VA Medical Center, Gainesville, Florida using Fisher’s exact test and Mann Whitney U testfo...

Sorafenib treatment is suggested for patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). This study aimed if combining local-regional sorafenib adds benefit who had tumor progression after three sessions of TACE within 12 months. We retrospectively analyzed the outcomes alone and combined therapies in HCC using inverse probabilit...

Hepatocellular carcinoma (HCC) is common cancer in the world. Hepatitis B/C or alcoholic cirrhosis is usually underlying condition. Surgical resection is curative treatment for small HCC, however most patients usually present when advanced or inoperable disease. Transarterial chemoembolization (TACE) is most common alternative treatment for early and advanced HCC. Curative treatment is possible...

BACKGROUND Transarterial Chemoembolization (TACE) has been recognized as a successful way of managing symptomatic and/or progressive hepatic carcinoid metastases not amenable to surgical resection. Although it is a fairly safe procedure, it is not without its complications. CASE PRESENTATION This is a case of a 53 year-old woman with a patent foramen ovale (PFO) and mild pulmonary hypertensio...

Background and Aims: Intermediate stage hepatocellular carcinoma (HCC) can be treated by transarterial chemoembolization (TACE). However, there appear to be side effects, such as induction of proangiogenic factors, e.g. vascular endothelial growth factor (VEGF), which have been shown to be associated with a poor prognosis. This prospective study was designed to compare serum VEGF level response...

AIM To identify clinical biomarkers that could early predict improved survival in patients with advanced-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization combined with sorafenib (TACE-S). METHODS We retrospectively evaluated the medical records of consecutive patients with advanced-stage HCC who underwent TACE-S from January 2012 to December 2015. At the first...

PURPOSE We aimed to compare the overall (OS) and disease-free survival (DFS) of patients undergoing orthotopic liver transplant (OLT) for hepatocellular carcinoma who did and did not have neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE). METHODS This is a retrospective study of 94 patients with HCC transplanted between 2000 and 2014 in a single tertiary cen...

Background and Aim: For intermediate HCC (hepatocellular carcinoma) with preserved liver function, Transarterial chemoembolization (TACE) is a standard therapy. Underlying disease reduces the net functionality of liver, hence post-TACE hepatic decompensation an important complication.Various pretreatment predictors have been studied to predict outcomes in HCC.Child-Pugh score ALBI are used asse...